Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carisoprodol
Drug ID BADD_D00370
Description Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications [A176047]. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential for abuse in addition to a low risk of dependence [L5074].
Indications and Usage Carisoprodol is indicated for the relief of discomfort related to acute, painful musculoskeletal conditions [FDA label]. **Important limitations of use** [FDA label]: • Should only be used for acute treatment periods up to two or three weeks • Adequate evidence of effectiveness for more prolonged use has not been established • Not recommended in pediatric patients less than 16 years of age
Marketing Status approved
ATC Code M03BA02
DrugBank ID DB00395
KEGG ID D00768
MeSH ID D002328
PubChem ID 2576
TTD Drug ID D05PLH
NDC Product Code 55700-836; 65862-158; 65862-693; 0591-5513; 65862-260; 55289-049; 58657-645; 63629-8479; 63629-9145; 68071-3421; 71205-339; 71610-430; 66064-5001; 77777-112; 43063-824; 45865-984; 50742-656; 63629-8478; 64980-380; 71610-531; 72189-386; 55700-907; 60429-508; 63629-1169; 64980-381; 70518-2800; 71610-617; 72789-190; 80425-0291; 50090-5953; 52536-682; 55700-954; 63187-786; 71205-241; 71335-1203; 52286-0021; 50090-5955; 51525-5901; 52536-688; 60760-397; 51927-3169; 16571-780; 29033-207; 42543-700; 70518-3131; 71205-704; 71335-9613; 72789-016; 72789-019; 72789-182; 17381-080; 72643-017; 16714-510; 61919-878; 0037-2001; 0037-2250; 70518-2618; 71335-0693; 71335-9621; 76333-135; 50228-109; 63629-9144; 67296-1404; 69584-111; 17337-0406; 29033-214; 62135-241; 63629-1168; 63629-2416; 63629-8477; 72189-310; 16571-781
UNII 21925K482H
Synonyms Carisoprodol | Isopropylmeprobamate | Isomeprobamate | Carisoprodate | Isobamate | Carisoma | Mio Relax | Soma | Vanadom | Soprodol | Somalgit
Chemical Information
Molecular Formula C12H24N2O4
CAS Registry Number 78-44-4
SMILES CCCC(C)(COC(=O)N)COC(=O)NC(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute hepatic failure09.01.03.0010.000126%Not Available
Agitation19.06.02.001; 17.02.05.0120.000314%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000188%
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000126%Not Available
Ataxia17.02.02.001; 08.01.02.004--
Back pain15.03.04.005--
Cardiac arrest02.03.04.0010.001758%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.001067%Not Available
Coma17.02.09.0010.000439%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.004457%Not Available
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.0070.000188%
Delusion19.10.01.0010.000188%
Dependence19.07.06.0080.000126%Not Available
Depressed level of consciousness17.02.04.0020.000251%
Depression19.15.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.06.0100.001532%Not Available
Drug dependence19.07.06.0110.000502%Not Available
Drug hypersensitivity10.01.01.0010.003628%Not Available
Drug withdrawal syndrome19.07.06.013; 08.06.02.0040.000803%Not Available
Dyspepsia07.01.02.001--
Feeling abnormal08.01.09.0140.000552%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Hepatic fibrosis24.08.06.002; 09.01.04.0020.000188%Not Available
Hiccups22.12.01.001; 07.01.06.009--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000126%
Hypersensitivity10.01.03.0030.000854%
Hypertension24.08.02.0010.000126%
Hypotension24.06.03.0020.000188%
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene